MannKind (MNKD)
(Delayed Data from NSDQ)
$6.00 USD
+0.17 (2.92%)
Updated Jul 16, 2024 03:56 PM ET
After-Market: $6.01 +0.01 (0.17%) 5:34 PM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
Brokerage Reports
MannKind Corporation [MNKD]
Reports for Purchase
Showing records 101 - 120 ( 228 total )
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Recent Drug Launch Weekly Retail Sales Tracker - Week Ended March 6
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Discontinuation of Coverage of the Biotech Sector
Provider: Brinson Patrick Securities Corporation
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
2Q''14 Update; Model Changes from SNY Deal
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Global Sanofi Deal: Finds Ideal Strategic Partner
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
A Giant Leap - FDA approves Afrezza for type 1 and type 2 diabetes
Provider: Griffin Securities, Inc.
Analyst: MARKEY K
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Raising Price Target to $15.00 on FDA approval of Afrezza
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
1Q''14 Update: Eagerly Anticipating Afrezza Approval.
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
1Q''14 Update: Eagerly Anticipating Afrezza Approval
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C